ObsEva, a clinical-stage pharma developing therapies for women's reproductive health, raised $97 million by offering 6.5 million shares at $15, within the range of $14 to $16. ObsEva plans to list on the Nasdaq under the symbol OBSV. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal.
